Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
Profitability
Gross margin51.3%-5.7pp57%+1.7pp55.2%
Operating margin-2,500.7%-1,240pp-1,260.8%+132pp-1,392.9%+105pp-1,498.3%+25.8pp-1,524.1%+1,721pp
Net margin-2,454.6%-1,216pp-1,238.5%+142pp-1,380.7%+109pp-1,489.7%+24.9pp-1,514.6%+1,710pp
EBITDA margin-2,380.8%-1,174pp-1,206.8%+137pp-1,343.7%+110pp-1,453.6%+27.7pp-1,481.3%+1,685pp
Free cash flow margin-1,409.7%-784pp-625.6%-82.5pp-543.2%+20.0pp-563.2%
Returns
Return on assets-94.9%+70.2pp-165.1%-58.6pp-106.5%-5.2pp-101.3%-12.6pp-88.6%+21.7pp
Efficiency
Asset turnover-0.1×0.1×+0.1×0.1×0.0×0.1×0.0×0.1×0.0×
Liquidity
Current ratio2.5×+1.3×1.3×-1.5×2.8×-1.2×+0.3×3.7×+2.1×
Quick ratio2.5×+1.3×1.2×-1.5×2.7×-1.2×3.9×+0.2×3.7×+2.1×
Cash ratio2.3×+1.4×-1.5×2.4×-1.2×3.7×+0.4×3.2×+2.0×
Leverage
Debt-to-assets0.1×-0.1×0.1×+0.1×0.1×0.0×0.1×0.0×0.1×
Per Share
Book value per share-$0.31+70.0%-$1.03-260%-$0.29-937%$0.03-91.4%$0.40+142%
Valuation
Market capitalization$185.35M+92.3%
Enterprise value$160.03M+113%
Price / sales95.1×+72.5×
EV / sales82.1×+64.4×
Free cash flow yield-14.8%+10.1pp
Earnings yield-25.8%+40.0pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are Insight Molecular Diagnostics Inc. Common Stock's profit margins?
Insight Molecular Diagnostics Inc. Common Stock (IMDX) runs a 51.3% gross margin and a -2500.7% operating margin, with a -2454.6% net margin.
Where do Insight Molecular Diagnostics Inc. Common Stock's ratios come from?
Every ratio is computed from Insight Molecular Diagnostics Inc. Common Stock's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.